KR102580705B1 - 치료제의 장 전달을 위한 제제 - Google Patents

치료제의 장 전달을 위한 제제 Download PDF

Info

Publication number
KR102580705B1
KR102580705B1 KR1020197013487A KR20197013487A KR102580705B1 KR 102580705 B1 KR102580705 B1 KR 102580705B1 KR 1020197013487 A KR1020197013487 A KR 1020197013487A KR 20197013487 A KR20197013487 A KR 20197013487A KR 102580705 B1 KR102580705 B1 KR 102580705B1
Authority
KR
South Korea
Prior art keywords
therapeutic agent
nanoparticles
formulation
insulin
sensitive polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197013487A
Other languages
English (en)
Korean (ko)
Other versions
KR20190086446A (ko
Inventor
인두 자베리
칼리아파나다르 넬라이아팬
Original Assignee
큐리릭스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐리릭스 인코포레이티드 filed Critical 큐리릭스 인코포레이티드
Priority to KR1020237031642A priority Critical patent/KR20230135694A/ko
Publication of KR20190086446A publication Critical patent/KR20190086446A/ko
Application granted granted Critical
Publication of KR102580705B1 publication Critical patent/KR102580705B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
KR1020197013487A 2016-10-12 2017-10-12 치료제의 장 전달을 위한 제제 Active KR102580705B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237031642A KR20230135694A (ko) 2016-10-12 2017-10-12 치료제의 장 전달을 위한 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/291,480 2016-10-12
US15/291,480 US11491114B2 (en) 2016-10-12 2016-10-12 Formulations for enteric delivery of therapeutic agents
PCT/US2017/056320 WO2018071655A1 (en) 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031642A Division KR20230135694A (ko) 2016-10-12 2017-10-12 치료제의 장 전달을 위한 제제

Publications (2)

Publication Number Publication Date
KR20190086446A KR20190086446A (ko) 2019-07-22
KR102580705B1 true KR102580705B1 (ko) 2023-09-19

Family

ID=61830540

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197013487A Active KR102580705B1 (ko) 2016-10-12 2017-10-12 치료제의 장 전달을 위한 제제
KR1020237031642A Pending KR20230135694A (ko) 2016-10-12 2017-10-12 치료제의 장 전달을 위한 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237031642A Pending KR20230135694A (ko) 2016-10-12 2017-10-12 치료제의 장 전달을 위한 제제

Country Status (8)

Country Link
US (2) US11491114B2 (https=)
EP (1) EP3525772A4 (https=)
JP (1) JP7046081B2 (https=)
KR (2) KR102580705B1 (https=)
CN (1) CN110049759A (https=)
AU (2) AU2017341753B2 (https=)
CA (1) CA3078570A1 (https=)
WO (1) WO2018071655A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019097251A1 (en) * 2017-11-17 2019-05-23 Intract Pharma Limited Novel compositions
BR112021019612A2 (pt) * 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
CN111743880B (zh) * 2020-06-05 2022-03-08 浙江大学医学院附属第一医院 一种单抗类药物口服纳米-微球制剂及其制备方法
US11365248B2 (en) 2020-06-29 2022-06-21 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating COVID-19 by inhalation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20100021549A1 (en) 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US20130034589A1 (en) 2011-08-04 2013-02-07 Nano And Advanced Materials Institute Limited pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY
US20160206741A1 (en) 2015-01-14 2016-07-21 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
ATE167396T1 (de) 1993-02-22 1998-07-15 Alza Corp Mittel zur oralen gabe von wirkstoffen
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
EP1429731B1 (en) 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
AU2004277419B2 (en) * 2003-09-30 2007-10-11 Brown University Research Foundation Nanoparticulate therapeutic biologically active agents
US20050170004A1 (en) 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20040224019A1 (en) 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541028B2 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US20080241260A1 (en) * 2005-09-28 2008-10-02 Padma Venkitachalam Devarajan Compositions for Enhanced Absorption of Biologically Active Agents
WO2008031770A2 (en) 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2008073558A2 (en) 2006-10-05 2008-06-19 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
CN102083423A (zh) * 2008-05-06 2011-06-01 葛兰素集团有限公司 生物活性剂的囊封方法
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
FR2934161B1 (fr) * 2008-07-28 2010-09-17 Flamel Tech Sa Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules.
GB0815852D0 (en) * 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
CN102614498B (zh) * 2011-01-28 2014-12-17 四川科伦药物研究有限公司 一种胰岛素纳米粒及其制备方法
US20140120162A1 (en) 2011-06-06 2014-05-01 Perosphere Inc. Bioadhesive Drug Delivery Compositions
EP2548571A1 (en) * 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
CN102908332B (zh) * 2011-08-04 2014-04-16 纳米及先进材料研发院有限公司 用于口服胰岛素递送的包含阳离子纳米粒子的肠溶包衣胶囊
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
CN104094119A (zh) 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
EP3778696A1 (en) 2012-04-23 2021-02-17 NanoProteagen Ltd. Polymeric nanoparticles and a process of preparation thereof
CN105142631A (zh) * 2013-01-14 2015-12-09 健康诊所有限公司 抗癌药物和用途
US9833522B2 (en) * 2013-12-23 2017-12-05 The Research Foundation For The State University Of New York Graphene-based contrast agents for photoacoustic and thermoacoustic tomography and method of use
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
US9370488B2 (en) 2014-07-21 2016-06-21 Kimia Zist Parsian Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
CN104739806B (zh) * 2015-04-17 2018-04-03 黑龙江大学 口服胰岛素复合微囊及制备方法
CN105056212B (zh) * 2015-07-14 2018-06-15 江西省药物研究所 一种提高胰岛素口服结肠吸收的壳聚糖纳米粒及制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20100021549A1 (en) 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US20130034589A1 (en) 2011-08-04 2013-02-07 Nano And Advanced Materials Institute Limited pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY
US20160206741A1 (en) 2015-01-14 2016-07-21 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Experimental &Molecular Medicine 48:8262(2016.10.07.)
International Journal of Nanomedicine 6:2429-2435(2011.10.18.)
J Nanobiotechnol 14:39 (2016.05.26.)

Also Published As

Publication number Publication date
AU2017341753A1 (en) 2019-05-30
CN110049759A (zh) 2019-07-23
US12594246B2 (en) 2026-04-07
BR112019007539A2 (pt) 2019-07-02
US20180098946A1 (en) 2018-04-12
AU2017341753B2 (en) 2023-12-07
US20230034964A1 (en) 2023-02-02
JP2019534897A (ja) 2019-12-05
EP3525772A1 (en) 2019-08-21
CA3078570A1 (en) 2018-04-19
US11491114B2 (en) 2022-11-08
AU2024201438A1 (en) 2024-03-21
JP7046081B2 (ja) 2022-04-01
EP3525772A4 (en) 2020-06-03
WO2018071655A1 (en) 2018-04-19
KR20190086446A (ko) 2019-07-22
KR20230135694A (ko) 2023-09-25

Similar Documents

Publication Publication Date Title
US12594246B2 (en) Formulations for enteric delivery of therapeutic agents
KR101483203B1 (ko) 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물
RU2663687C2 (ru) Композиции наночастиц альбумина и паклитаксела
CN101474155B (zh) 注射用肺靶向载药前体脂质体及其使用方法
US9149441B2 (en) Nanospheres encapsulating bioactive material and method for formulation of nanospheres
Moritz et al. Recent developments in the application of polymeric nanoparticles as drug carriers
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
CA2936493C (en) Nanoencapsulation of hydrophilic active compounds
CN105412935A (zh) 一种基于n-(2-羟丙基)甲基丙烯酰胺聚合物的纳米粒及其制备方法
CN102188377B (zh) 包载药物脂质体的制备方法
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
EP3452013B1 (en) Coated implants for long-term controlled release of antibody therapeutics
Das et al. Chitosan-based systems for oral drug delivery applications
CN102188379B (zh) 载药脂质体的制备方法
CN106924184B (zh) 一种眼部玻璃体注射用多囊脂质体及其制备方法
BR112019007539B1 (pt) Formulação oral de um agente terapêutico, método de preparação de uma formulação administrável por via oral de um agente terapêutico e uso da referida formulação oral
JP2010514679A (ja) 制御放出組成物及び方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190510

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201012

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221024

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230619

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230915

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230915

End annual number: 3

Start annual number: 1

PG1601 Publication of registration